Skip to main content

Table 2 COPD prevalence (%)* in major demographic subgroups using the fixed ratio criterion (FEV1/FVC<0.70)

From: Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010

  Fixed ratio criterion (FEV1/FVC<0.70)
Estimates based on pre- bronchodilator spirometry dataa Estimates based on pre and post-bronchodilator spirometry datab
Original exam weights (n = 5532) Weights adjusted for non-response (n = 5532) Original exam weights (n = 4986) Pre-BR and Post-BR weights adjusted for non-response (n = 4986) Post-BR missing data imputed then Pre-BR weights adjusted for non-response (n = 5532)
Overall 20.3 (1.1) 20.9 (1.1) 8.3 (0.7) 14.0 (1.0) 13.7 (0.8)
   Stage I (Mild)c 10.9 (0.7) 11.0 (0.7) 5.0 (0.6) 7.9 (0.8) 7.2 (0.5)
   Stage II (Moderate)c 7.8 (0.6) 8.0 (0.6) 2.4 (0.2) 4.7 (0.5) 5.0 (0.4)
   Stage III and IV (Severe/Very Severe)c 1.1 (0.2) 1.2 (0.2) 0.3 (0.1) 0.7 (0.2) 0.8 (0.2)
Age      
   40–59 15.4 (1.2) 15.6 (1.2) 6.2 (0.7) 9.4 (1.0) 9.2 (0.9)
   60–79 30.7 (1.3) 31.2 (1.3) 13.3 (1.1) 23.0 (1.7) 22.6 (1.2)
Gender      
   Male 24.1 (1.2) 24.8 (1.3) 11.4 (0.9) 17.4 (1.2) 17.4 (1.0)
   Female 16.7 (1.3) 17.3 (1.3) 5.4 (0.6) 10.8 (1.3) 10.4 (0.8)
Race and ethnic origin      
   Non-Hispanic white 22.5 (1.2) 22.9 (1.2) 9.5 (0.8) 15.0 (1.1) 14.9 (0.9)
   Non-Hispanic black 17.4 (1.3) 18.0 (1.4) 6.9 (0.9) 14.1 (2.0) 12.8 (1.3)
   Mexican-American 10.1 (.7) 10.4 (0.7) 2.7 (0.6) 5.4 (1.1) 5.8 (0.8)
  1. *Standard errors of the estimates are given in parentheses.
  2. Adults Aged 40–79 Years: NHANES 2007-10.
  3. aEstimates based on pre-bronchodilator included those who completed the pre-bronchodilator test plus those persons excluded from pre-BR spirometry who had a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy.
  4. bEstimates based on pre and post-bronchodilator included those who completed the pre-bronchodilator test and were not selected for the post-bronchodilator test (no disease), plus those persons who completed the post-bronchodilator test, plus those persons excluded from pre-BR spirometry who had a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy. The 546 persons who did not complete the post-bronchodilator test are included in the numerator of the imputed estimates as their post-bronchodilator data was multiply imputed.
  5. cSpirometric classification used the following cutoffs per GOLD specifications: Mild (Stage 1): PPFEV1 ≥ 80%, Moderate (Stage 2): 50% ≤PPFEV1 < 80%, Severe and Very severe (Stages 3 and 4): PPFEV1 < 50%.